Smith & Nephew: Capitalizing on Viscosupplementation Growth Amid Rising Osteoarthritis Prevalence
- The viscosupplementation market is projected to grow from US$ 4.66 billion in 2024 to US$ 10.16 billion by 2033.
- Smith & Nephew can capitalize on the growing demand for non-surgical arthritis treatments through innovative product development.
- The company's focus on effective viscosupplementation solutions can enhance patient outcomes and maintain its competitive edge in orthopedics.
Growth Trajectory of Viscosupplementation: A Key Opportunity for Smith & Nephew
The global viscosupplementation market is witnessing substantial growth, presenting significant opportunities for companies in the medical device sector, including Smith & Nephew plc. According to a recent report, the market is projected to increase from approximately US$ 4.66 billion in 2024 to around US$ 10.16 billion by 2033, achieving a compound annual growth rate (CAGR) of 9.02% from 2025 to 2033. This growth is largely fueled by the rising prevalence of osteoarthritis (OA) and osteoporosis, alongside a consumer shift towards minimally invasive treatment options. As more patients seek alternatives to surgical interventions, the demand for viscosupplementation therapies is expected to rise substantially.
The increasing incidence of osteoarthritis, which currently affects around 15% of individuals aged 30 and older, underscores the urgency for effective treatment solutions. The World Health Organization reports that 528 million people were affected by OA in 2019, with projections indicating that this number could reach 1 billion by 2050. Contributing factors include an aging population and rising obesity rates, both of which are linked to higher OA prevalence. In this context, the need for therapies that enhance mobility and delay the requirement for total knee replacements becomes critical. Hyaluronic acid-based injections, a prominent form of viscosupplementation, have gained traction as a preferred non-surgical treatment option, especially when traditional conservative methods do not yield results.
The trend towards non-surgical therapies is indicative of broader shifts in patient preferences, with many seeking solutions that minimize recovery time and postoperative complications. As a leading player in the orthopedic device market, Smith & Nephew is well-positioned to capitalize on this growing demand for viscosupplementation products. By advancing their portfolio in this area, the company can address the increasing need for effective arthritis treatments, thereby improving patient quality of life and maintaining a competitive edge in the industry.
In addition to the promising market growth, the report emphasizes the importance of innovation in product offerings. Companies that invest in research and development to create more effective viscosupplementation solutions may find themselves leading the market. As the landscape evolves, partnerships and collaborations within the healthcare sector will be essential for driving advancements in treatment options.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

